To access this element change to forms mode OFF
Grant Award View - GA166523
A Phase III randomised placebo-controlled trial of mirtazapine as a...
GA ID:
GA166523
Agency:
Department of Health and Aged Care
Approval Date:
7-May-2021
Publish Date:
25-May-2021
Category:
Health and Medical Research
Grant Term:
1-Jun-2021 to 31-May-2025
Value (AUD):
$4,899,579.86
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 20/21 1.1 Health Policy Research and Analysis
Grant Program:
2020_MRFF_Efficient_Use_of_Existing_Medicines
Grant Activity:
A Phase III randomised placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine ("Ice") dependence
Purpose:
Crystalline methamphetamine ('ice') is a growing concern in Australia. There are no approved medications that can be used to treat dependence on this drug. This clinical trial will examine whether mirtazapine, a newly identified treatment agent for methamphetamine use, can be used safely and effectively in routine clinical care to manage methamphetamine dependence in Australia.
GO ID:
GO Title:
MRFF – PPHR Initiative – 2020 Efficient Use of Existing Medicines Grant Opportunity
Internal Reference ID:
MRF2007155
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Sydney
Town/City:
Sydney
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, UNITED STATES